Callisto's Atiprimod may stabilize multiple myeloma, study says

By Angela McDaniels

Seattle, Dec. 14 - Callisto Pharmaceuticals Inc. said two multiple myeloma patients exhibited stable disease after being treated with Atiprimod, the company's cancer drug candidate, in a phase 1/2a clinical trial.

In addition, one patient experienced a 34% decrease in M protein over three months of treatment and two patients reported a subjective decrease in bone pain, the company said.

The phase 1/2a clinical trial of Atiprimod includes 15 patients with relapsed or refractory multiple myeloma patients.

The highest dose being dispensed is 180 mg per day. Callisto said it plans to continue this trial at higher dose levels until a maximum tolerated dose is reached and then treat 10 additional patients at that level.

The data was presented on Dec. 11 and Dec. 12 at the American Society of Hematology annual meeting in Atlanta.

"The large attendance at this multiple myeloma session at which we presented demonstrates the high level of interest among the hematology and cancer research community for new drug candidates such as Atiprimod," executive vice president of research and development Donald Picker said in a company news release. Callisto put the audience at about 1,000 people.

"So far, the Atiprimod research has demonstrated encouraging indications and we are looking forward to additional clinical data to further evaluate its efficacy. Continued clinical development of Atiprimod is a major strategic focus for Callisto."

Multiple myeloma is a serious and ultimately fatal blood cancer that creates devastating complications including bone resorption and skeletal compression fractures, the company said.

Callisto is a biopharmaceutical company based in New York that develops new drugs to treat cancer and other serious afflictions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.